Literature DB >> 23292503

Increased CCT-eta expression is a marker of latent and active disease and a modulator of fibroblast contractility in Dupuytren's contracture.

Latha Satish1, David B O'Gorman, Sandra Johnson, Christina Raykha, Bing Siang Gan, James H-C Wang, Sandeep Kathju.   

Abstract

Dupuytren's contracture (DC) is a fibroproliferative disorder of unknown etiology characterized by a scar-like contracture that develops in the palm and/or digits. We have previously reported that the eta subunit of the chaperonin containing T-complex polypeptide (CCT-eta) is increased in fibrotic wound healing, and is essential for the accumulation of α-smooth muscle actin (α-SMA) in fibroblasts. The purpose of this study was to determine if CCT-eta is similarly implicated in the aberrant fibrosis seen in DC and to investigate the role of CCT-eta in the behavior of myo/fibroblasts in DC. Fibroblasts were obtained from DC-affected palmar fascia, from adjacent phenotypically normal palmar fascia in the same DC patients (PF), and from non-DC palmar fascial tissues in patients undergoing carpal tunnel (CT) release. Inherent contractility in these three populations was examined using fibroblast-populated collagen lattices (FPCLs) and by cell traction force microscopy. Expression of CCT-eta and α-SMA protein was determined by Western blot. The effect of CCT-eta inhibition on the contractility of DC cells was determined by deploying an siRNA versus CCT-eta. DC cells were significantly more contractile than both matching palmar fascial (PF) cells and CT cells in both assays, with PF cells demonstrating an intermediate contractility in the FPCL assay. Whereas α-SMA protein was significantly increased only in DC cells compared to PF and CT cells, CCT-eta protein was significantly increased in both PF and DC cells compared to CT cells. siRNA-mediated depletion of CCT-eta inhibited the accumulation of both CCT-eta and α-SMA protein in DC cells, and also significantly decreased the contractility of treated DC cells. These observations suggest that increased expression of CCT-eta appears to be a marker for latent and active disease in these patients and to be essential for the increased contractility exhibited by these fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23292503      PMCID: PMC3682020          DOI: 10.1007/s12192-012-0392-9

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


  38 in total

Review 1.  Flexible substrata for the detection of cellular traction forces.

Authors:  Karen A Beningo; Yu-Li Wang
Journal:  Trends Cell Biol       Date:  2002-02       Impact factor: 20.808

2.  Traction fields, moments, and strain energy that cells exert on their surroundings.

Authors:  James P Butler; Iva Marija Tolić-Nørrelykke; Ben Fabry; Jeffrey J Fredberg
Journal:  Am J Physiol Cell Physiol       Date:  2002-03       Impact factor: 4.249

Review 3.  On the origin and spread of Dupuytren's disease.

Authors:  Robert M McFarlane
Journal:  J Hand Surg Am       Date:  2002-05       Impact factor: 2.230

4.  Flexible polyacrylamide substrata for the analysis of mechanical interactions at cell-substratum adhesions.

Authors:  Karen A Beningo; Chun-Min Lo; Yu-Li Wang
Journal:  Methods Cell Biol       Date:  2002       Impact factor: 1.441

5.  Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells.

Authors:  Liaquat Suleman Verjee; Kim Midwood; Dominique Davidson; Mark Eastwood; Jagdeep Nanchahal
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

6.  Determining substrate displacement and cell traction fields--a new approach.

Authors:  Zhaochun Yang; Jeen-Shang Lin; Jianxin Chen; James H-C Wang
Journal:  J Theor Biol       Date:  2006-05-19       Impact factor: 2.691

Review 7.  Dupuytren's disease: history, diagnosis, and treatment.

Authors:  Robert B Shaw; Alphonsus K S Chong; Andrew Zhang; Vincent R Hentz; James Chang
Journal:  Plast Reconstr Surg       Date:  2007-09       Impact factor: 4.730

8.  Differential expression of chaperonin containing T-complex polypeptide (CCT) subunits during fetal and adult skin wound healing.

Authors:  Latha Satish; Adam Abdulally; Duane Oswald; Sandra Johnson; Fen Ze Hu; J Christopher Post; Garth D Ehrlich; Sandeep Kathju
Journal:  Cell Stress Chaperones       Date:  2008-05-09       Impact factor: 3.667

9.  The correlation of in vivo burn scar contraction with the level of α-smooth muscle actin expression.

Authors:  Xue-Qing Wang; Olena Kravchuk; Clay Winterford; Roy M Kimble
Journal:  Burns       Date:  2011-08-19       Impact factor: 2.744

10.  Reversal of TGF-β1 stimulation of α-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's-derived fibroblasts.

Authors:  Latha Satish; Phillip H Gallo; Mark E Baratz; Sandra Johnson; Sandeep Kathju
Journal:  BMC Musculoskelet Disord       Date:  2011-05-25       Impact factor: 2.362

View more
  4 in total

1.  Chaperonin containing T-complex polypeptide subunit eta is a potential marker of joint contracture: an experimental study in the rat.

Authors:  Ronghan He; Zhe Wang; Yunxiang Lu; Junqi Huang; Jianhua Ren; Kun Wang
Journal:  Cell Stress Chaperones       Date:  2015-07-30       Impact factor: 3.667

2.  Anti-fibrotic action of pirfenidone in Dupuytren's disease-derived fibroblasts.

Authors:  Chaoming Zhou; Fang Liu; Phillip H Gallo; Mark E Baratz; Sandeep Kathju; Latha Satish
Journal:  BMC Musculoskelet Disord       Date:  2016-11-11       Impact factor: 2.362

3.  Management of limited joint mobility in diabetic patients.

Authors:  Michele Abate; Cosima Schiavone; Vincenzo Salini; Isabel Andia
Journal:  Diabetes Metab Syndr Obes       Date:  2013-05-07       Impact factor: 3.168

4.  Comprehensive analysis of the expression of chaperonin containing TCP1 subunits (CCTs) and their influence on prognosis in hepatocellular carcinoma.

Authors:  Rongdang Fu; Shaotao Jiang; Zhanwen Guan; Jieyuan Li; Xiaohong Zhang; Huanwei Chen
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.